Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

BACKGROUND: We previously reported a trial using a DNA vaccine encoding prostatic acid phosphatase (MVI-816, pTVG-HP), given over 12 weeks concurrently or sequentially with pembrolizumab, in patients with mCRPC. We report the final analysis of this trial following two additional treatment arms in wh...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeel, Douglas G, Eickhoff, Jens C, Wargowski, Ellen, Johnson, Laura E, Kyriakopoulos, Christos E, Emamekhoo, Hamid, Lang, Joshua M, Brennan, Mary Jane, Liu, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919462/
https://www.ncbi.nlm.nih.gov/pubmed/35277461
http://dx.doi.org/10.1136/jitc-2021-004198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919462/
https://www.ncbi.nlm.nih.gov/pubmed/35277461
http://dx.doi.org/10.1136/jitc-2021-004198

Ejemplares similares